Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 543 entries
Sorted by: Best Match Show Resources per page
Serotonin syndrome with paroxetine overdose: a case report.

Primary care companion to the Journal of clinical psychiatry

Canan F, Korkmaz U, Kocer E, Onder E, Yildirim S, Ataoglu A.
PMID: 18458731
Prim Care Companion J Clin Psychiatry. 2008;10(2):165-7. doi: 10.4088/pcc.v10n0213g.

No abstract available.

Cite
Canan F, Korkmaz U, Kocer E, et al. Serotonin syndrome with paroxetine overdose: a case report. Prim Care Companion J Clin Psychiatry. 2008;10(2):165-7doi: 10.4088/pcc.v10n0213g.
Canan, F., Korkmaz, U., Kocer, E., Onder, E., Yildirim, S., & Ataoglu, A. (2008). Serotonin syndrome with paroxetine overdose: a case report. Primary care companion to the Journal of clinical psychiatry, 10(2), 165-7. https://doi.org/10.4088/pcc.v10n0213g
Canan, Fatih, et al. "Serotonin syndrome with paroxetine overdose: a case report." Primary care companion to the Journal of clinical psychiatry vol. 10,2 (2008): 165-7. doi: https://doi.org/10.4088/pcc.v10n0213g
Canan F, Korkmaz U, Kocer E, Onder E, Yildirim S, Ataoglu A. Serotonin syndrome with paroxetine overdose: a case report. Prim Care Companion J Clin Psychiatry. 2008;10(2):165-7. doi: 10.4088/pcc.v10n0213g. PMID: 18458731; PMCID: PMC2292445.
Copy Download .nbib Format: NLM
Headache and hormone replacement therapy in the postmenopausal woman.

Current treatment options in neurology

MacGregor EA.
PMID: 19094831
Curr Treat Options Neurol. 2009 Jan;11(1):10-7. doi: 10.1007/s11940-009-0002-z.

Headache and migraine are common symptoms of the menopause, often associated with irregular periods, hot flashes, and night sweats. Perimenopausal women should routinely be asked about headache and migraine, so that they can be offered appropriate advice. If attacks...

Cite
MacGregor EA. Headache and hormone replacement therapy in the postmenopausal woman. Curr Treat Options Neurol. 2009;11(1):10-7doi: 10.1007/s11940-009-0002-z.
MacGregor, E. A. (2009). Headache and hormone replacement therapy in the postmenopausal woman. Current treatment options in neurology, 11(1), 10-7. https://doi.org/10.1007/s11940-009-0002-z
MacGregor, E Anne. "Headache and hormone replacement therapy in the postmenopausal woman." Current treatment options in neurology vol. 11,1 (2009): 10-7. doi: https://doi.org/10.1007/s11940-009-0002-z
MacGregor EA. Headache and hormone replacement therapy in the postmenopausal woman. Curr Treat Options Neurol. 2009 Jan;11(1):10-7. doi: 10.1007/s11940-009-0002-z. PMID: 19094831.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.

Primary care companion to the Journal of clinical psychiatry

Pearlstein TB, Bellew KM, Endicott J, Steiner M.
PMID: 15841196
Prim Care Companion J Clin Psychiatry. 2005;7(2):53-60. doi: 10.4088/pcc.v07n0203.

Objective: To compare the efficacy and safety of paroxetine controlled release (CR) (12.5 mg/day or 25 mg/day) versus placebo in premenstrual dysphoric disorder (PMDD).Method: A double-blind, randomized, placebo-controlled trial was conducted over 3 menstrual cycles in women aged 18-45...

Cite
Pearlstein TB, Bellew KM, Endicott J, et al. Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial. Prim Care Companion J Clin Psychiatry. 2005;7(2):53-60doi: 10.4088/pcc.v07n0203.
Pearlstein, T. B., Bellew, K. M., Endicott, J., & Steiner, M. (2005). Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial. Primary care companion to the Journal of clinical psychiatry, 7(2), 53-60. https://doi.org/10.4088/pcc.v07n0203
Pearlstein, Teri B, et al. "Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial." Primary care companion to the Journal of clinical psychiatry vol. 7,2 (2005): 53-60. doi: https://doi.org/10.4088/pcc.v07n0203
Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial. Prim Care Companion J Clin Psychiatry. 2005;7(2):53-60. doi: 10.4088/pcc.v07n0203. PMID: 15841196; PMCID: PMC1079696.
Copy Download .nbib Format: NLM
Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine.

Primary care companion to the Journal of clinical psychiatry

Kato O, Misawa H.
PMID: 16163406
Prim Care Companion J Clin Psychiatry. 2005;7(4):202. doi: 10.4088/pcc.v07n0412a.

No abstract available.

Cite
Kato O, Misawa H. Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Prim Care Companion J Clin Psychiatry. 2005;7(4):202doi: 10.4088/pcc.v07n0412a.
Kato, O., & Misawa, H. (2005). Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Primary care companion to the Journal of clinical psychiatry, 7(4), 202. https://doi.org/10.4088/pcc.v07n0412a
Kato, On, and Misawa, Hitoshi. "Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine." Primary care companion to the Journal of clinical psychiatry vol. 7,4 (2005): 202. doi: https://doi.org/10.4088/pcc.v07n0412a
Kato O, Misawa H. Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Prim Care Companion J Clin Psychiatry. 2005;7(4):202. doi: 10.4088/pcc.v07n0412a. PMID: 16163406; PMCID: PMC1192440.
Copy Download .nbib Format: NLM
St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated.

Evidence-based mental health

Ernst E.
PMID: 16246883
Evid Based Ment Health. 2005 Nov;8(4):107. doi: 10.1136/ebmh.8.4.107.

No abstract available.

Cite
Ernst E. St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated. Evid Based Ment Health. 2005;8(4):107doi: 10.1136/ebmh.8.4.107.
Ernst, E. (2005). St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated. Evidence-based mental health, 8(4), 107. https://doi.org/10.1136/ebmh.8.4.107
Ernst, Edzard. "St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated." Evidence-based mental health vol. 8,4 (2005): 107. doi: https://doi.org/10.1136/ebmh.8.4.107
Ernst E. St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated. Evid Based Ment Health. 2005 Nov;8(4):107. doi: 10.1136/ebmh.8.4.107. PMID: 16246883.
Copy Download .nbib Format: NLM
Biological therapies for obsessive-compulsive disorder.

Journal of psychiatric practice

Fallon BA, Mathew SJ.
PMID: 15990479
J Psychiatr Pract. 2000 May;6(3):113-28. doi: 10.1097/00131746-200005000-00002.

Two treatments have demonstrated efficacy in OCD, exposure and response (ritual) prevention (EX/RP) and pharmacotherapy with serotonin reuptake inhibitors (SRIs). In this article, which is the third in a three-part series, the authors present an overview of the role...

Cite
Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000;6(3):113-28doi: 10.1097/00131746-200005000-00002.
Fallon, B. A., & Mathew, S. J. (2000). Biological therapies for obsessive-compulsive disorder. Journal of psychiatric practice, 6(3), 113-28. https://doi.org/10.1097/00131746-200005000-00002
Fallon, B A, and Mathew, S J. "Biological therapies for obsessive-compulsive disorder." Journal of psychiatric practice vol. 6,3 (2000): 113-28. doi: https://doi.org/10.1097/00131746-200005000-00002
Fallon BA, Mathew SJ. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract. 2000 May;6(3):113-28. doi: 10.1097/00131746-200005000-00002. PMID: 15990479.
Copy Download .nbib Format: NLM
SSRI efficacy-finding the right dose.

Journal of psychiatric practice

Caley CF, Kando JC.
PMID: 15985852
J Psychiatr Pract. 2002 Jan;8(1):33-40. doi: 10.1097/00131746-200201000-00005.

The selective serotonin reuptake inhibitors (SSRIs) are a class of effective, well-tolerated antidepressants. They have a number of benefits compared with the tricyclic antidepressants (TCAs) including improved safety in overdose, reduced side-effect burden, and uncomplicated dosing regimens. To avoid...

Cite
Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract. 2002;8(1):33-40doi: 10.1097/00131746-200201000-00005.
Caley, C. F., & Kando, J. C. (2002). SSRI efficacy-finding the right dose. Journal of psychiatric practice, 8(1), 33-40. https://doi.org/10.1097/00131746-200201000-00005
Caley, Charles F, and Kando, Judith C. "SSRI efficacy-finding the right dose." Journal of psychiatric practice vol. 8,1 (2002): 33-40. doi: https://doi.org/10.1097/00131746-200201000-00005
Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract. 2002 Jan;8(1):33-40. doi: 10.1097/00131746-200201000-00005. PMID: 15985852.
Copy Download .nbib Format: NLM
QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

Annals of general psychiatry

Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM.
PMID: 15845138
Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1.

BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic...

Cite
Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1doi: 10.1186/1744-859X-4-1.
Sala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J. R., Caverzasi, E., Bonzano, A., Piccinelli, M., Barale, F., & De Ferrari, G. M. (2005). QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Annals of general psychiatry, 4(1), 1. https://doi.org/10.1186/1744-859X-4-1
Sala, Michela, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Annals of general psychiatry vol. 4,1 (2005): 1. doi: https://doi.org/10.1186/1744-859X-4-1
Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1. PMID: 15845138; PMCID: PMC1088007.
Copy Download .nbib Format: NLM
Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention.

Psychiatry (Edgmont (Pa. : Township))

Cahill SP, Pontoski K, D'Olio CM.
PMID: 21120107
Psychiatry (Edgmont). 2005 Sep;2(9):34-46.

Posttraumatic stress disorder is a common and often chronic and disabling anxiety disorder that can develop after exposure to highly stressful events characterized by actual or threatened harm to the self or others. This is the second of two...

Cite
Cahill SP, Pontoski K, D'Olio CM. Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention. Psychiatry (Edgmont). 2005;2(9):34-46
Cahill, S. P., Pontoski, K., & D'Olio, C. M. (2005). Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention. Psychiatry (Edgmont (Pa. : Township)), 2(9), 34-46.
Cahill, Shawn P, et al. "Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention." Psychiatry (Edgmont (Pa. : Township)) vol. 2,9 (2005): 34-46.
Cahill SP, Pontoski K, D'Olio CM. Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention. Psychiatry (Edgmont). 2005 Sep;2(9):34-46. PMID: 21120107; PMCID: PMC2993535.
Copy Download .nbib Format: NLM
Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

The primary care companion for CNS disorders

Thase ME, Ninan PT, Musgnung JJ, Trivedi MH.
PMID: 21731835
Prim Care Companion CNS Disord. 2011;13(1). doi: 10.4088/PCC.10m00979blu.

BACKGROUND: This randomized, open-label, rater-blinded, multicenter study compared treatment outcomes with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release (ER) with selective serotonin reuptake inhibitors (SSRIs) in primary care patients with major depressive disorder.METHOD: Study data were collected from...

Cite
Thase ME, Ninan PT, Musgnung JJ, et al. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord. 2011;13(1)doi: 10.4088/PCC.10m00979blu.
Thase, M. E., Ninan, P. T., Musgnung, J. J., & Trivedi, M. H. (2011). Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. The primary care companion for CNS disorders, 13(1), . https://doi.org/10.4088/PCC.10m00979blu
Thase, Michael E, et al. "Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study." The primary care companion for CNS disorders vol. 13,1 (2011). doi: https://doi.org/10.4088/PCC.10m00979blu
Thase ME, Ninan PT, Musgnung JJ, Trivedi MH. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord. 2011;13(1). doi: 10.4088/PCC.10m00979blu. PMID: 21731835; PMCID: PMC3121209.
Copy Download .nbib Format: NLM
A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire.

Therapeutics and clinical risk management

Arafa M, Shamloul R.
PMID: 18472973
Ther Clin Risk Manag. 2007 Aug;3(4):527-31.

AIM: This study reports the results of a large prospective single-blinded clinical trial of 3 SSRI (paroxetine, fluoxetine and escitalopram) in PE using a validated questionnaire.METHODS: A total of 100 normally potent men suffering from PE were enrolled in...

Cite
Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag. 2007;3(4):527-31
Arafa, M., & Shamloul, R. (2007). A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Therapeutics and clinical risk management, 3(4), 527-31.
Arafa, Mohamed, and Shamloul, Rany. "A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire." Therapeutics and clinical risk management vol. 3,4 (2007): 527-31.
Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag. 2007 Aug;3(4):527-31. PMID: 18472973; PMCID: PMC2374931.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 543 entries